SMA Type 1 | vzw Victorkracht
Bij Victor werd op de leeftijd van 3 maanden de uiterst zeldzame spierziekte SMA Type 1 vastgesteld. Om Victor te steunen werd de vzw Victorkracht opgericht. Word ook vriend van Victor en schenk hem Victorkracht!
Related Articles
Qure’s Chest X-ray AI gets FDA nod for lung nodule detection
Qure.ai secures 13th FDA clearance for qXR-LN, benefiting Radiologists, Pulmonologists, and ER physicians, widening the scope for detecting lung cancer early
Digital transformation and the care experience
Chang Gung Memorial Hospital superintendent Dr Chien-Tzung Chen relays what challenges the health system overcame to achieve EMRAM Stage 7 and the benefit of embracing…
(1) Post | LinkedIn
Speaking at a Westminster Health Forum policy conference on AI in health and social care Dominic Cushnan Director of AI, Imaging, and Deployment for NHS…
Dr. Ruchi V D on LinkedIn: NVIDIA Partners With NHS Trusts to Deploy AI Platform in UK Hospitals |…
A consortium of 10 National Health Service Trusts — the publicly funded healthcare system in England — is now deploying the MONAI-based AIDE platform across…
Post | LinkedIn
#𝑪𝒉𝒂𝒕𝑮𝑷𝑻 𝑯𝒂𝒔 𝑷𝒂𝒔𝒔𝒆𝒅 𝒂 𝑹𝒂𝒅𝒊𝒐𝒍𝒐𝒈𝒚 𝑩𝒐𝒂𝒓𝒅 𝑬𝒙𝒂𝒎- 𝑩𝒊𝒈 𝒅𝒆𝒂𝒍? 🤔 Interesting resources to read if you are interested in the use of #ChatGPT in #Radiology…
Post | LinkedIn
Large-language models have become popular for a variety of uses, including in medicine, and #radiologists are exploring the pros and cons of using them. #ChatGPT…
Recommendations | Head injury: assessment and early management | Guidance | NICE
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the…
Lung Cancer | AI-aided early detection of lung-cancer
Our solutions are used for screening high-risk population for Lung cancer. Increasing chances for incidental or opportunistic findings of malignant nodules.
Lung Cancer | AI-aided early detection of lung-cancer
Our solutions are used for screening high-risk population for Lung cancer. Increasing chances for incidental or opportunistic findings of malignant nodules.